FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/11/077509 [Registered on: 29/11/2024] Trial Registered Prospectively
Last Modified On: 21/11/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Unani
Other (Specify) [Therapeutic]  
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Evaluation of efficacy of Dawa e Dhayabitus in Diabetes mellitus type 2 
Scientific Title of Study   A randomized, parallel group, open label, active controlled clinical study to evaluate safety and efficacy of Dawa-i-Dhayabitus in Dhayabitus Harr Qism Thani (Diabetes Mellitus Type 2)  
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Saiyed Fatema Anjum 
Designation  PG Scholar 
Affiliation  National Research Institute of Unani Medicine for Skin Disorders Hyderabad 
Address  Department of Moalajat, National Research Institute Of Unani Medicine for Skin Disorder, AG colony Road, opp. ESI Hospital, Erragadda, Hyderabad

Hyderabad
TELANGANA
500038
India 
Phone  7620282464  
Fax    
Email  sydfatema09@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Prof Mohammad Nasar 
Designation  Professor 
Affiliation  National Research Institute of Unani Medicine for Skin Disorders Hyderabad 
Address  Department of Moalajat, National Research Institute Of Unani Medicine for Skin Disorder, AG colony Road, opp. ESI Hospital, Erragadda, Hyderabad

Hyderabad
TELANGANA
500038
India 
Phone  8328446962  
Fax    
Email  drnasar.nriumsd@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Saiyed Fatema Anjum 
Designation  PG Scholar 
Affiliation  National Research Institute of Unani Medicine for Skin Disorders  
Address  Department of Moalajat, National Research Institute Of Unani Medicine for Skin Disorder, AG colony Road, opp. ESI Hospital, Erragadda, Hyderabad

Hyderabad
TELANGANA
500038
India 
Phone  7620282464  
Fax    
Email  sydfatema09@gmail.com  
 
Source of Monetary or Material Support  
National Research Institute Of Unani Medicine for Skin Disorders, AG colony Road, Opp. ESI Hospital, Erragadda, Hyderabad 500038 
 
Primary Sponsor  
Name  National Research Institute Of Unani Medicine for Skin Disorders 
Address  National Research Institute Of Unani Medicine for Skin Disorders, AG colony Road, Opp. ESI Hospital, Erragadda, Hyderabad-500038 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Saiyed Fatema Anjum  National Research Institute Of Unani Medicine for Skin Disorders  Moalajat OPD No. 1, Dept. of Moalajat, OPD Block,National Research Institute of Unani Medicine for Skin Disorders. AGs Colony Road, Opp. ESI Hospital, Erragadda, Hyderabad- 500038
Hyderabad
TELANGANA 
7620282464

sydfatema09@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee, NRIUMSD, Hyderabad   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: E119||Type 2 diabetes mellitus without complications,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Dawā’-i-Dhayābīṭus  Dose & Route of Administration: 2.5g SafÅ«f (Powder) twice daily orally with water Duration of therapy:12 weeks  
Comparator Agent  Tablet Metformin  Dose: 500mg twice daily orally after meals Duration of therapy: 12 weeks 
 
Inclusion Criteria  
Age From  30.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  Fasting Blood Glucose (FBG) Levels between 126 and 150 mg/dL  
(after 8-12 hours of fasting) 
or 
Post-Prandial Blood Glucose (PPBG) Level between 200 and 250 mg/dL 
(after 2 hours of ingestion of meal) 
Glycated Haemoglobin (HbA1c) between 6.5% and 8%  
Patients willing to sign the written informed consent   
with / without 
Presence of any of the following symptoms of Dhayābīṭus Ḥārr Qism Thānī (Type 2 Diabetes Mellitus):   
Uṭash Mufriṭ (Polydipsia)  
Kathrat-i-Bawl (Polyuria)  
Kathrat-i-Ishtiha (Polyphagia)  
Bawl Layli (Nocturia) 
Burning sensation in palms and soles 
Naqs al-Wazn (Weight Loss)  
I’ya (Fatigue)  
Ḍu‘f-i-‘Ām (General Weakness) 
 
 
ExclusionCriteria 
Details   
 
Method of Generating Random Sequence   Permuted block randomization, fixed 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Change in Fasting Blood Glucose (FBG), Post Prandial Blood Glucose (PPBG), HbA1c from baseline to post treatment at 12 weeks   At baseline, 2, 4, 6, 8, 10 and 12 weeks  
 
Secondary Outcome  
Outcome  TimePoints 
Improvement in symptoms on VAS from baseline to post treatment at 12 weeks   At baseline, 2, 4, 6, 8, 10 and 12 weeks  
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   05/12/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

As per the WHO, diabetes mellitus is defined as a heterogeneous metabolic disorder characterized by common feature of chronic hyperglycemia with disturbance of carbohydrate, fat and protein metabolism.

Diabetes Mellitus is a leading cause of morbidity and mortality world over. It is expected to continue as a major health problem owing to its serious complications, especially end stage renal disease, IHD, gangrene of the lower extremities, and blindness in the adults. The rise in prevalence is more for Type 2 DM than Type 1DM.

Diabetes is a major health issue that has reached alarming levels. Today, more than half a billion people are living with diabetes worldwide. According to IDF Atlas in 2021, it is estimated that 537 million people have diabetes, and this number is projected to reach 643 million by 2030, and 783 million by 2045. In addition, 541 million people are estimated to have impaired glucose tolerance in 2021. Direct health expenditures due to diabetes are already close to one trillion USD and will exceed this figure by 2030.

Despite of advances in the treatment of Diabetes Mellitus, it becomes the major epidemic among NCDs. Treatment for diabetes mellitus includes insulin therapy and oral antidiabetic drugs. Oral anti-diabetic drugs include sulphonylureas(glimepiridegliclazides), biguanides (metformin), thiazolidinediones(pioglitazone), DPP-4 inhibitors (sitagliptinvildagliptin), and SGLT2 inhibitors (dapagliflozin), but these drugs have certain adverse effects, such as abdominal discomfort, nausea, vomiting, diarrhea, weight gain.[3,4] Therefore, search of safe and effective drug for Diabetes Mellitus is the thrust area for research in medical fields.

Unani system of medicine (USM) offers treatment for Diabetes Mellitus type 2. Many classical prescriptions comprising single herbo-mineral drugs and pharmacopoeial formulations have been recommended for the management of diabetes mellitus type 2, which are safe and cost effective, such as Qurá¹£-i-TabāshÄ«r,Qurá¹£-i-Kafoor, Qurá¹£-i-DhayābīṭusSafÅ«f DhayābīṭusQurá¹£-i-GulnārKushtaBaidha Murgh. Some of these drugs mentioned in Unani classical literature have not been explored scientifically regarding their safety and efficacy. Dawā’-i-Dhayābīṭus is one of the compound formulations described by physicians in classical Unani literature for the management of Dhayābīṭus á¸¤Ärr, but its safety and efficacy has not been evaluated on scientific parameters. Therefore, present clinical trial entitled â€œA Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Safety and Efficacy of Dawā’-i-Dhayābīṭus in Dhayābīṭus á¸¤Ärr Qism ThānÄ« (Diabetes Mellitus Type 2)” has been planned.

 
Close